{"id":"NCT03390036","sponsor":"Anika Therapeutics, Inc.","briefTitle":"Study of Cingal for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide at 39 Weeks Follow up","officialTitle":"Trial Extension Protocol to Add a 39 Week Follow Up to Cingal 16-02, a Randomized, Double-Blind, Active Comparator Controlled, Multi-Center Study of a Single Injection of Cingal to Provide Symptomatic Relief of Knee Osteoarthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-12-07","primaryCompletion":"2018-07-30","completion":"2018-07-30","firstPosted":"2018-01-04","resultsPosted":"2023-05-31","lastUpdate":"2023-05-31"},"enrollment":526,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Knee Osteoarthritis"],"interventions":[{"type":"COMBINATION_PRODUCT","name":"Cingal","otherNames":["HA + TH"]},{"type":"DEVICE","name":"Monovisc","otherNames":["HA"]},{"type":"DRUG","name":"Triamcinolone Hexacetonide","otherNames":["TH"]}],"arms":[{"label":"Cingal","type":"EXPERIMENTAL"},{"label":"Monovisc","type":"ACTIVE_COMPARATOR"},{"label":"Triamcinolone Hexacetonide (TH)","type":"ACTIVE_COMPARATOR"}],"summary":"Extension study to Cingal 16-02 to obtain 39-week safety and efficacy follow-up data","primaryOutcome":{"measure":"OMERACT-OARSI Responder Rate at 39 Weeks","timeFrame":"39 weeks","effectByArm":[{"arm":"Cingal","deltaMin":91.2,"sd":null},{"arm":"Monovisc","deltaMin":92.4,"sd":null},{"arm":"Triamcinolone Hexacetonide (TH)","deltaMin":93.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.8106"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":17,"countries":["Hungary","Poland"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":233},"commonTop":["Headache","Arthralgia","Viral upper respiratory tract infection","Musculoskeletal pain","Spinal pain"]}}